Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

Inclusion Criteria: * Patients with confirmed diagnosis of COVID-19 admitted to hospital; * Duration of symptoms related to hospitalization ≤ 14 days; * Patients ≥ 18 year old; * D-dimer above the upper limit of normal (collected until 72 hours before the randomization); * Agreement to participate by providing the informed consent form (ICF). Exclusion Criteria: * Patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis); * Platelets \< 50,000 /mm3 * Need for ASA therapy \> 100 mg; * Need for P2Y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel); * Chronic use of non-hormonal anti-inflammatory drugs; * Sustained uncontrolled systolic blood pressure (BP) of ≥180 mmHg or diastolic BP of ≥100 mmHg; * INR \> 1,5; * Patients contraindicated to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator); * Criteria for disseminated intravascular coagulation (DIC); * A history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (AV) malformation, or aneurysm; * Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy; * Hypersensitivity to rivaroxaban; * Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) (e.g. protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort); * Known HIV infection; * Creatinine clearance \< 30 ml/min according to the Cockcroft-Gault Formula; * Pregnancy or breastfeeding.